17.51
Schlusskurs vom Vortag:
$17.41
Offen:
$17.34
24-Stunden-Volumen:
1.56M
Relative Volume:
1.02
Marktkapitalisierung:
$3.05B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.6832
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+2.82%
1M Leistung:
+15.88%
6M Leistung:
+15.58%
1J Leistung:
-40.16%
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-580-3099
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Vergleichen Sie IMVT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IMVT
Immunovant Inc
|
17.51 | 3.03B | 0 | -382.71M | -325.64M | -2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-10-14 | Eingeleitet | Truist | Hold |
2025-07-10 | Fortgesetzt | Goldman | Neutral |
2025-03-03 | Eingeleitet | Jefferies | Hold |
2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-10-09 | Bestätigt | Oppenheimer | Outperform |
2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
2024-03-13 | Eingeleitet | Goldman | Buy |
2024-02-20 | Eingeleitet | JP Morgan | Overweight |
2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-10-13 | Hochstufung | UBS | Neutral → Buy |
2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-05-01 | Eingeleitet | BofA Securities | Buy |
2023-04-25 | Eingeleitet | Citigroup | Buy |
2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
2023-03-30 | Eingeleitet | Stifel | Buy |
2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2022-09-26 | Herabstufung | UBS | Buy → Neutral |
2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
2021-06-01 | Herabstufung | Stifel | Buy → Hold |
2020-10-28 | Eingeleitet | UBS | Buy |
2020-10-12 | Eingeleitet | Guggenheim | Buy |
2020-10-08 | Eingeleitet | Stifel | Buy |
2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
2020-08-25 | Eingeleitet | Raymond James | Outperform |
2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Why Immunovant Inc. stock is popular among millennialsMarket Volume Report & Low Drawdown Momentum Trade Ideas - newser.com
Trend analysis for Immunovant Inc. this week2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
Can Immunovant Inc. stock continue upward trendJuly 2025 Patterns & Entry Point Strategy Guides - nchmf.gov.vn
What analyst consensus says on Immunovant Inc. stockOptions Play & AI Driven Stock Price Forecasts - nchmf.gov.vn
Why Immunovant Inc. stock remains undervalued2025 Buyback Activity & Consistent Return Investment Signals - nchmf.gov.vn
Why Immunovant Inc. stock attracts global investorsBear Alert & AI Enhanced Trading Alerts - nchmf.gov.vn
What sentiment indicators say about Immunovant Inc. stockWeekly Risk Summary & Low Volatility Stock Suggestions - nchmf.gov.vn
Published on: 2025-10-18 11:37:29 - nchmf.gov.vn
Published on: 2025-10-18 07:11:53 - nchmf.gov.vn
Will Immunovant Inc. stock outperform value stocksWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com
Visualizing Immunovant Inc. stock with heatmapsWeekly Loss Report & Consistent Return Investment Signals - newser.com
Reversal indicators forming on Immunovant Inc. stockTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Key resistance and support levels for Immunovant Inc.Quarterly Trade Report & Community Consensus Trade Alerts - newser.com
Truist Securities initiates Immunovant stock with Hold rating, $16 target - Investing.com
Statistical indicators supporting Immunovant Inc.’s strengthJuly 2025 Movers & Expert Approved Momentum Ideas - newser.com
How analysts rate Immunovant Inc. stock todayJuly 2025 Review & Free Technical Pattern Based Buy Signals - newser.com
Analyzing drawdowns of Immunovant Inc. with statistical toolsPortfolio Growth Summary & Stock Timing and Entry Methods - newser.com
How hedge fund analytics apply to Immunovant Inc. stockDollar Strength & Short-Term Trading Alerts - newser.com
Immunovant (NASDAQ:IMVT) Insider Michael Geffner Sells 1,272 Shares - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Up 7.2%Here's What Happened - MarketBeat
Immunovant’s chief technology officer sells $25,835 in stock By Investing.com - Investing.com South Africa
Immunovant’s chief technology officer sells $25,835 in stock - Investing.com India
Will breakout in Immunovant Inc. lead to full recovery2025 Technical Patterns & AI Driven Price Predictions - newser.com
Immunovant Inc. stock momentum explainedMarket Weekly Review & Daily Growth Stock Investment Tips - newser.com
Smart tools for monitoring Immunovant Inc.’s price action2025 Earnings Impact & Weekly Top Gainers Trade List - newser.com
JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - MSN
Published on: 2025-10-09 06:28:21 - newser.com
Using Ichimoku Cloud for Immunovant Inc. technicalsMarket Activity Summary & Real-Time Volume Analysis Alerts - newser.com
Is Immunovant Inc. forming a bottoming baseJuly 2025 Decliners & Community Trade Idea Sharing Platform - newser.com
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):